Abstract：
Bacterial biofilms on the sinonasal mucosa, especially biofilms of Staphylococcus aureus, are associated with greater severity and recalcitrance of chronic rhinosinusitis (CRS). There are few, if any, antibiofilm agents suitable for sinonasal application available for the management of this problem. Nasodine® Nasal Spray (Nasodine) is a 0.5% povidone-iodine-based formulation that has been developed for sinonasal application. We investigated the antibiofilm efficacy of Nasodine to determine whether it may be a candidate for the treatment of biofilm-associated CRS.
Biofilms of S. aureus ATCC 6538 were grown in vitro using the Centers for Disease Control biofilm reactor. Intact biofilms were treated by immersion in 0.9% saline (control), half concentration Nasodine, or full concentration Nasodine for between 5 min and 6 h. Further biofilm cells were dispersed into suspension then treated for between 30 s and 5 min. Surviving bacteria were then enumerated by culture and counting colonies, and the log10 reduction in viable bacteria was compared with control.
Nasodine demonstrated time and concentration-dependent bacterial killing against intact biofilm. Statistically significant reductions in viable bacteria from intact biofilms were seen with exposures as brief as 5 min. Nasodine consistently eradicated dispersed biofilm within 1 min.
Nasodine is highly active against biofilms of S. aureus ATCC 6538 in vitro. Biofilm killing is impeded by the presence of the intact biofilm structure.
In chronic rhinosinusitis (CRS), bacterial communities called biofilms are associated with more severe inflammation. An iodine-based nasal spray called Nasodine almost completely eradicates bacterial biofilms after 6 h of exposure. Nasodine may be useful for treating CRS. Laryngoscope, 133:2490-2495, 2023.
Biofilms of S. aureus ATCC 6538 were grown in vitro using the Centers for Disease Control biofilm reactor. Intact biofilms were treated by immersion in 0.9% saline (control), half concentration Nasodine, or full concentration Nasodine for between 5 min and 6 h. Further biofilm cells were dispersed into suspension then treated for between 30 s and 5 min. Surviving bacteria were then enumerated by culture and counting colonies, and the log10 reduction in viable bacteria was compared with control.
Nasodine demonstrated time and concentration-dependent bacterial killing against intact biofilm. Statistically significant reductions in viable bacteria from intact biofilms were seen with exposures as brief as 5 min. Nasodine consistently eradicated dispersed biofilm within 1 min.
Nasodine is highly active against biofilms of S. aureus ATCC 6538 in vitro. Biofilm killing is impeded by the presence of the intact biofilm structure.
In chronic rhinosinusitis (CRS), bacterial communities called biofilms are associated with more severe inflammation. An iodine-based nasal spray called Nasodine almost completely eradicates bacterial biofilms after 6 h of exposure. Nasodine may be useful for treating CRS. Laryngoscope, 133:2490-2495, 2023.
摘要：
目的：鼻窦粘膜上的细菌生物膜，尤其是金黄色葡萄球菌的生物膜，与慢性鼻窦炎（CRS）的严重程度和顽固性有关。很少,如果有的话,适用于鼻腔鼻窦应用的抗生物膜剂可用于解决此问题。Nasodine®鼻喷雾剂（Nasodine）是一种基于0.5％聚维酮碘的制剂，已开发用于鼻窦应用。我们研究了Nasodine的抗生物膜功效，以确定它是否可能是治疗生物膜相关CRS的候选药物。
方法:使用疾病控制中心生物膜反应器在体外培养金黄色葡萄球菌ATCC6538的生物膜。完整的生物膜通过浸入0.9%盐水（对照）进行处理，半浓度Nasodine,或完全浓度的Nasodine持续5分钟至6小时。将进一步的生物膜细胞分散到悬浮液中,然后处理30秒至5分钟。然后通过培养和计数菌落来计数存活细菌，并将活细菌的log10减少量与对照进行了比较。
结果：Nasodine显示出时间和浓度依赖性细菌对完整生物膜的杀伤作用。用短暂的5分钟的暴露观察到来自完整生物膜的活细菌的统计学显著减少。Nasodine在1分钟内始终根除分散的生物膜。
结论：Nasodine在体外对金黄色葡萄球菌ATCC6538的生物膜具有高度活性。完整生物膜结构的存在阻碍了生物膜杀伤。
背景：在慢性鼻窦炎（CRS）中，被称为生物膜的细菌群落与更严重的炎症有关。一种名为Nasodine的基于碘的鼻喷雾剂在暴露6小时后几乎完全根除了细菌生物膜。Nasodine可用于治疗CRS。喉镜,2023年。
方法:使用疾病控制中心生物膜反应器在体外培养金黄色葡萄球菌ATCC6538的生物膜。完整的生物膜通过浸入0.9%盐水（对照）进行处理，半浓度Nasodine,或完全浓度的Nasodine持续5分钟至6小时。将进一步的生物膜细胞分散到悬浮液中,然后处理30秒至5分钟。然后通过培养和计数菌落来计数存活细菌，并将活细菌的log10减少量与对照进行了比较。
结果：Nasodine显示出时间和浓度依赖性细菌对完整生物膜的杀伤作用。用短暂的5分钟的暴露观察到来自完整生物膜的活细菌的统计学显著减少。Nasodine在1分钟内始终根除分散的生物膜。
结论：Nasodine在体外对金黄色葡萄球菌ATCC6538的生物膜具有高度活性。完整生物膜结构的存在阻碍了生物膜杀伤。
背景：在慢性鼻窦炎（CRS）中，被称为生物膜的细菌群落与更严重的炎症有关。一种名为Nasodine的基于碘的鼻喷雾剂在暴露6小时后几乎完全根除了细菌生物膜。Nasodine可用于治疗CRS。喉镜,2023年。
